FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2024391750> ?p ?o ?g. }

• W2024391750 endingPage "23" @default.
• W2024391750 startingPage "23" @default.
• W2024391750 abstract "Tofacitinib, an orally administered Janus kinase inhibitor, blocks signaling through γ-chain–containing cytokines (interleukins 2, 4, 7, 9, 15, and 21). We performed a phase 2 trial to measure its efficacy in patients with moderate-to-severe active Crohn’s disease.Patients (N = 139; age, ≥18 y) with moderate-to-severe active Crohn’s disease were assigned randomly to groups given 1 mg (n = 36), 5 mg (n = 34), or 15 mg (n = 35) tofacitinib or placebo (n = 34), twice daily for 4 weeks, at 48 centers in 12 countries. The primary end point was the proportion of clinical responders at week 4 (decrease from baseline in the Crohn’s Disease Activity Index score of ≥70 points [Response-70]). Secondary end points included clinical remission (Crohn’s Disease Activity Index score of <150 points) at week 4.A clinical response was observed in 36% (P = .467), 58% (P = .466), and 46% (P ≥ .999) of patients given the 1-, 5-, and 15-mg doses of tofacitinib, compared with 47% of patients given placebo. Clinical remission was observed in 31% (P = .417), 24% (P = .776), and 14% (P = .540) of patients given the 1-, 5-, and 15-mg doses of tofacitinib, compared with 21% of patients given placebo. The 15-mg dose of tofacitinib reduced levels of C-reactive protein and fecal calprotectin from baseline. Adverse and serious adverse events were similar among groups. Dose-dependent increases in low- and high-density lipoprotein cholesterol were observed in patients given the 5- or 15-mg doses of tofacitinib.There were no significant differences in the percentage of patients with moderate-to-severe active Crohn’s disease who achieved clinical responses (Response-70) or clinical remission after 4 weeks' administration of tofacitinib (1, 5, or 15 mg) or placebo twice daily. However, a large percentage of patients given placebo achieved Response-70 or remission. Reductions in C-reactive protein and fecal calprotectin levels among patients given the 15-mg dose of tofacitinib indicate its biologic activity. ClinicalTrials.gov number: NCT00615199." @default.
• W2024391750 created "2016-06-24" @default.
• W2024391750 creator A5009520444 @default.
• W2024391750 creator A5016943515 @default.
• W2024391750 creator A5024636509 @default.
• W2024391750 creator A5055703231 @default.
• W2024391750 creator A5064605211 @default.
• W2024391750 creator A5068222850 @default.
• W2024391750 creator A5080261136 @default.
• W2024391750 date "2004-01-01" @default.
• W2024391750 modified "2023-10-01" @default.
• W2024391750 title "35 Pneumopathie à pneumocystis jiroveci chez les patients non infectés par le VIH : analyse de 7 observations et revue de la littérature" @default.
• W2024391750 doi "https://doi.org/10.1016/s0761-8425(04)71661-7" @default.
• W2024391750 hasPublicationYear "2004" @default.
• W2024391750 type Work @default.
• W2024391750 sameAs 2024391750 @default.
• W2024391750 citedByCount "0" @default.
• W2024391750 crossrefType "journal-article" @default.
• W2024391750 hasAuthorship W2024391750A5009520444 @default.
• W2024391750 hasAuthorship W2024391750A5016943515 @default.
• W2024391750 hasAuthorship W2024391750A5024636509 @default.
• W2024391750 hasAuthorship W2024391750A5055703231 @default.
• W2024391750 hasAuthorship W2024391750A5064605211 @default.
• W2024391750 hasAuthorship W2024391750A5068222850 @default.
• W2024391750 hasAuthorship W2024391750A5080261136 @default.
• W2024391750 hasConcept C126322002 @default.
• W2024391750 hasConcept C142724271 @default.
• W2024391750 hasConcept C197934379 @default.
• W2024391750 hasConcept C204787440 @default.
• W2024391750 hasConcept C27081682 @default.
• W2024391750 hasConcept C2777575956 @default.
• W2024391750 hasConcept C2778886723 @default.
• W2024391750 hasConcept C71924100 @default.
• W2024391750 hasConcept C90924648 @default.
• W2024391750 hasConceptScore W2024391750C126322002 @default.
• W2024391750 hasConceptScore W2024391750C142724271 @default.
• W2024391750 hasConceptScore W2024391750C197934379 @default.
• W2024391750 hasConceptScore W2024391750C204787440 @default.
• W2024391750 hasConceptScore W2024391750C27081682 @default.
• W2024391750 hasConceptScore W2024391750C2777575956 @default.
• W2024391750 hasConceptScore W2024391750C2778886723 @default.
• W2024391750 hasConceptScore W2024391750C71924100 @default.
• W2024391750 hasConceptScore W2024391750C90924648 @default.
• W2024391750 hasLocation W20243917501 @default.
• W2024391750 hasOpenAccess W2024391750 @default.
• W2024391750 hasPrimaryLocation W20243917501 @default.
• W2024391750 hasRelatedWork W1892175722 @default.
• W2024391750 hasRelatedWork W2069871920 @default.
• W2024391750 hasRelatedWork W2153414586 @default.
• W2024391750 hasRelatedWork W2607842204 @default.
• W2024391750 hasRelatedWork W2766717228 @default.
• W2024391750 hasRelatedWork W2883187082 @default.
• W2024391750 hasRelatedWork W2981478968 @default.
• W2024391750 hasRelatedWork W3094078944 @default.
• W2024391750 hasRelatedWork W3157994245 @default.
• W2024391750 hasRelatedWork W4233016836 @default.
• W2024391750 hasVolume "21" @default.
• W2024391750 isParatext "false" @default.
• W2024391750 isRetracted "false" @default.
• W2024391750 magId "2024391750" @default.
• W2024391750 workType "article" @default.